RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience.

Tuckerman J, Cheng DR, Hunter G, Elia S, Hearn T, Verma D, Jacobs S, Carr J, Crawford NW

Open source

DOI
10.1002/hsr2.73066
Published
2026 Sep
Container
Health science reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hsr2.73066,
  title = {RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience.},
  author = {Tuckerman J and Cheng DR and Hunter G and Elia S and Hearn T and Verma D and Jacobs S and Carr J and Crawford NW},
  year = {2026},
  journal = {Health science reports},
  doi = {10.1002/hsr2.73066},
  url = {https://doi.org/10.1002/hsr2.73066}
}

RIS

TY  - JOUR
TI  - RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience.
AU  - Tuckerman J
AU  - Cheng DR
AU  - Hunter G
AU  - Elia S
AU  - Hearn T
AU  - Verma D
AU  - Jacobs S
AU  - Carr J
AU  - Crawford NW
PY  - 2026
JO  - Health science reports
DO  - 10.1002/hsr2.73066
UR  - https://doi.org/10.1002/hsr2.73066
ER  - 

APA

J, T., DR, C., G, H., S, E., T, H., D, V., S, J., J, C., & NW, C. (2026). RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience.. Health science reports. https://doi.org/10.1002/hsr2.73066

Source records